Hematology (all articles)
Cohort Study: Burden of long-term morbidity borne by survivors of acute myeloid leukemia treated with blood or marrow transplantation.
29 Jun, 2022 | 10:56h | UTC
Commentary on Twitter
We must understand life after BMT better, what it MEANS for a patient surviving intensive but curative treatment. Kudos to this @JCO_ASCO paper but we need better designs: versus other treatments, in BMT cohorts!
Life's gray, not categorical…#bmtsmhttps://t.co/E4YQV4LzoN pic.twitter.com/P7bMWXMTB5— Nico Gagelmann (@NicoGagelmann) June 23, 2022
Under a https://creativecommons.org/licenses/by-nc-nd/4.0/ license
Brief Review | Never above suspicion: getting to the bottom of cardiac sarcoidosis diagnosis and treatment.
29 Jun, 2022 | 10:50h | UTC
The 5th edition of the WHO classification of hematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms.
27 Jun, 2022 | 11:40h | UTCEditorial: The WHO Classification of Haematolymphoid Tumours – Leukemia
The 5th edition of the WHO classification of hematolymphoid tumors: lymphoid neoplasms.
27 Jun, 2022 | 11:38h | UTCEditorial: The WHO Classification of Haematolymphoid Tumours – Leukemia
Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.
24 Jun, 2022 | 11:13h | UTC
M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.
23 Jun, 2022 | 10:10h | UTC
5-year follow up of a RCT: Ruxolitinib versus best available therapy in inadequately controlled polycythemia vera without splenomegaly.
23 Jun, 2022 | 09:55h | UTCRuxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study – The Lancet Haematology (link to abstract – $ for full-text)
Original Study: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NEW online—5-year follow up of RESPONSE-2, a randomised, phase 3b study, supports the use of ruxolitinib as a second-line therapy of choice for patients with inadequately controlled polycythaemia vera without splenomegaly #mpnsm https://t.co/yuENmcJv0P pic.twitter.com/aogZJ6gonW
— The Lancet Haematology (@TheLancetHaem) May 19, 2022
RCT: Lisocabtagene maraleucel vs. standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma.
21 Jun, 2022 | 10:48h | UTCLisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Single-arm Phase II trial: Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent Non-Hodgkin Lymphomas.
20 Jun, 2022 | 00:51h | UTC
10-year outcomes of a RCT: Time to cure for childhood and young adult Acute Lymphoblastic Leukemia is independent of early risk factors.
20 Jun, 2022 | 00:49h | UTCTime to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Analysis of thromboembolic and thrombocytopenic events after the AstraZeneca, Pfizer, and Moderna COVID-19 vaccines in 3 Nordic countries.
15 Jun, 2022 | 11:17h | UTC
Recommendations Statement: Diagnosis and treatment of systemic mastocytosis.
14 Jun, 2022 | 11:03h | UTC
Cohort Study: Mortality among patients undergoing blood transfusion in relation to donor sex and parity.
14 Jun, 2022 | 10:56h | UTCNews Release: Red blood cell units from female blood donors do not increase risk of death of transfused patients – Karolinska Institutet
Molecular international prognostic scoring system for myelodysplastic syndromes.
14 Jun, 2022 | 10:38h | UTCMolecular International Prognostic Scoring System for Myelodysplastic Syndromes – NEJM Evidence
BSH guideline for the hematological management of major hemorrhage.
13 Jun, 2022 | 10:53h | UTC
2-year follow-up of a single-arm study: Ciltacabtagene Autoleucel, an Anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma.
13 Jun, 2022 | 07:34h | UTCOriginal Study: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
In follow-up from CARTITUDE-1 trial of ciltacabtagene autoleucel in R/R MM, ORR was 97.9% and 82.5% had a stringent CR. 27-mo PFS was 54% and OS was 70.4% https://t.co/cnpzkg5yKM
— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022
Systematic Review: Evidence-based perioperative diagnosis and management of pulmonary embolism.
9 Jun, 2022 | 10:34h | UTC
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
9 Jun, 2022 | 10:17h | UTC
International consensus classification of mature lymphoid neoplasms.
9 Jun, 2022 | 10:15h | UTC
Cardiac Magnetic Resonance Imaging–based screening for cardiac sarcoidosis in patients with atrioventricular block requiring temporary pacing.
8 Jun, 2022 | 10:41h | UTC
ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children.
7 Jun, 2022 | 10:52h | UTC
Oncologic emergencies and urgencies: A comprehensive review.
6 Jun, 2022 | 12:06h | UTCOncologic emergencies and urgencies: A comprehensive review – CA: A Cancer Journal for Clinicians
Commentary on Twitter
🎯Just in time for #ASCO22 | Oncologic emergencies and urgencies: A comprehensive review https://t.co/HyZmI37tr5 @BEGouldRothberg @YaleCancer @KeithDelman
CC: @OncoAlert pic.twitter.com/57tqiLXijN— CA: A Cancer Journal for Clinicians (@CACancerJournal) June 2, 2022
#ASCO22 – RCT: Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-Cell Lymphoma.
6 Jun, 2022 | 11:16h | UTCIbrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
#ASCO22 – RCT: Triplet therapy, transplantation, and maintenance until progression in myeloma.
6 Jun, 2022 | 11:06h | UTCTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo
— NEJM (@NEJM) June 5, 2022
#ASCO22 – Phase 1-2 single-arm study: Teclistamab in relapsed or refractory multiple myeloma.
6 Jun, 2022 | 11:11h | UTCTeclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine
Commentary on Twitter
MajesTEC-1: Teclistamab resulted in a high incidence of deep and durable response in patients with triple-class–exposed relapsed or refractory multiple myeloma. #ASCO22 https://t.co/Nanjob1q7p pic.twitter.com/oqfaiu8MOx
— NEJM (@NEJM) June 5, 2022